首页> 外文期刊>Epidemiology >Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.
【24h】

Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.

机译:对乙酰氨基酚和非甾体类抗炎药使用者中上消化道并发症的相对风险。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with an increase in upper gastrointestinal complications. There is no agreement, however, on whether all conventional NSAIDs have a similar relative risk (RR), and epidemiologic data are limited on acetaminophen. We studied the association between these medications and the risk of upper gastrointestinal bleed/perforation in a population-based cohort of 958,397 persons in the United Kingdom between 1993 and 1998. Our nested case-control analysis included 2,105 cases and 11,500 controls. RR estimates were adjusted for several factors known to be associated with upper gastrointestinal bleed/perforation. Compared with non-users, users of acetaminophen at doses less than 2 gm did not have an increased risk of upper gastrointestinal complications. The adjusted RR for acetaminophen at doses greater than 2 gm was 3.6 [95% confidence interval (95% CI) = 2.6-5.1]. The corresponding RRs for low/medium and high doses of NSAIDs were 2.4 (95% CI = 1.9-3.1) and 4.9 (95% CI = 4.1-5.8). The RR was 3.1 (95% CI = 2.5, 3.8) for short plasma half-life, 4.5 (95% CI = 3.5-5.9) for long half-life, and 5.4 (95% CI = 4.0-7.1) for slow-release formulations of NSAIDs. After adjusting for daily dose, the differences in RR between individual NSAIDs tended to diminish except for apazone. Users of H2 receptor antagonists, omeprazole, and misoprostol had RRs of 1.4 (95% CI = 1.2-1.8), 0.6 (95% CI = 0.4-0.9), and 0.6 (95% CI = 0.4-1.0), respectively. Among NSAID users, use of nitrates was associated with an RR of 0.6 (95% CI = 0.4-1.0).
机译:非甾体类抗炎药(NSAIDs)与上消化道并发症的增加有关。但是,关于所有常规的非甾体抗炎药是否都具有相似的相对危险性(RR),尚无共识,而且对乙酰氨基酚的流行病学数据有限。我们在1993年至1998年间以958,397名英国人群为基础的队列研究了这些药物与上消化道出血/穿孔风险之间的关系。我们的嵌套病例对照分析包括2,105例病例和11,500例对照。针对已知与上消化道出血/穿孔相关的几个因素调整了RR估计值。与非使用者相比,对乙酰氨基酚使用者的剂量小于2 gm并没有增加上消化道并发症的风险。剂量大于2 gm时对乙酰氨基酚的调整后RR为3.6 [95%置信区间(95%CI)= 2.6-5.1]。低/中,高剂量NSAID的相应RRs为2.4(95%CI = 1.9-3.1)和4.9(95%CI = 4.1-5.8)。短血浆半衰期的RR为3.1(95%CI = 2.5,3.8),长血浆半衰期的RR为4.5(95%CI = 3.5-5.9),慢速血浆半衰期为5.4(95%CI = 4.0-7.1)。释放非甾体抗炎药的配方。调整每日剂量后,除阿帕宗外,各个非甾体抗炎药之间的RR差异趋于减小。 H2受体拮抗剂,奥美拉唑和米索前列醇的使用者的RR分别为1.4(95%CI = 1.2-1.8),0.6(95%CI = 0.4-0.9)和0.6(95%CI = 0.4-1.0)。在NSAID用户中,使用硝酸盐的RR为0.6(95%CI = 0.4-1.0)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号